We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CytRx has announced that preliminary interim results from a novel polyvalent DNA + protein HIV vaccine Phase I clinical trial conducted at the University of Massachusetts Medical School will be presented at the AIDS Vaccine 2005 International Conference, to be held Sept.
YM BioSciences has reported that its subsidiary, DELEX Therapeutics, has received permission from Heath Canada to initiate a randomized Phase IIb study with AeroLEF, its unique formulation of the opioid, fentanyl, for the treatment of moderate-to-severe acute pain.
Altea Therapeutics announced the completion of a multicenter Phase II dose-ranging clinical study in acute pain for its hydromorphone transdermal patch.
Canadian drug developer Vasogen has halted a late-stage clinical trial of its lead product Celacade earlier than planned, after the drug wasn't shown to be very effective.
Alfacell has provided an update on the status of its international, confirmatory Phase IIIb malignant mesothelioma trial for Onconase (ranpirnase), the company's lead investigational drug candidate.
Swiss drug maker Novartis has announced that the FDA has granted priority review to its breast cancer treatment Femara to treat earlier forms of the disease.
MedImmune announced that it has licensed worldwide rights from GlaxoSmithKline (GSK) to develop certain antistaphylococcal monoclonal antibodies (MAbs).
Advaxis has successfully completed its preclinical toxicology studies of Lovaxin C, a Listeria cancer vaccine, for treatment of cervical and head and neck cancers.
Peregrine Pharmaceuticals and the New Approaches to Brain Tumor Therapy (NABTT) Consortium have initiated a clinical trial designed to confirm the dosing, safety and efficacy of a single intratumoral infusion of Cotara in the treatment of glioblastoma multiforme, a common and deadly form of brain cancer.